Launch Or License: Taking Your First Drug To Europe
Executive Summary
Directly launching a drug in Europe is the most difficult path for US-based biopharma companies, many of which decide to out-license rights for that territory. But, for the right asset, it’s also the most rewarding. The authors review 11 years of EMA approvals to examine European entry strategies’ effects on company valuations.